Turn Therapeutics Announces Peer-Reviewed Publication in Journal of Dermatological Treatment Highlighting GX-03 Activity in IL-36 Associated Inflammatory Model
Study demonstrates statistically significant reduction in disease severity in a murine dermatitis model characterized by IL-36 expression
First in a planned series of peer-reviewed publications exploring the scientific rationale and non-systemic mechanism underlying GX-03, currently in Phase 2 evaluation for moderate-to-severe atopic dermatitis
Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company focused on developing localized therapies for inflammatory and infectious skin diseases, today announced the publication of a peer-reviewed research article in the Journal of Dermatological Treatment evaluating the effects of its lead program, GX-03, in an IL-36–associated inflammatory environment.
The publication, titled “Effects of extended-release topical polyhexanide in a Staphylococcus aureus-induced murine dermatitis model characterized by IL-36 expression,” was co-authored by Bradley Burnam, Chief Executive Officer of Turn Therapeutics, and Stephen Bresnick, M.D., a practicing physician, researcher, and advisor to the Company.
